The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic
development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics
under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-
Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13,
20, 16, 1, 50, 47 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical
and Discovery stages comprises 3, 1, 9 and 21 molecules, respectively.
Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market
and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to
gain competitive advantage. The guide is built using data and information sourced from proprietary databases,
company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources. Additionally,
various dynamic tracking processes ensure that the most recent developments are captured on a real time
basis.
Request A Sample copy of This Report @ http://www.hexareports.com/report/hepatitis-c-pipeline-
review-h2-2017/request-sample
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and
relevance of data.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious
Disease).
The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and
universities/research institutes based on information derived from company and industry-specific
sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-
registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product
description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental
activities.
Reasons To Buy
1. Procure strategically important competitor information, analysis, and insights to formulate effective
R&D strategies.
Follow Us: